Mantle Cell Lymphoma Care From Diagnosis Through Relapse: Expert Guidance on Applying the Latest Evidence as Part of Clinical Routine
  • CME

Review practical guidance and the most recent data in this expert analysis of challenging MCL cases, including discussions on when to initiate therapy, how to select optimal first-line treatment, and what to do at progression.
Stephen Ansell, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: November 13, 2018 Expiration: November 12, 2019

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan therapeutic strategies for patients with mantle cell lymphoma based on diagnostic classification, patient age and fitness, and risk stratification
  • Integrate the available clinical data, treatment guidelines, and expert recommendations when selecting frontline treatment for patients with mantle cell lymphoma
  • Apply clinical data and expert recommendations when making treatment decisions for patients with relapsed/refractory mantle cell lymphoma, considering all available options including clinical trial enrollment
  • Evaluate the available clinical data on promising investigational agents and treatment approaches for appropriate patients with mantle cell lymphoma

Acknowledgements

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
AbbVie
AstraZeneca
Pharmacyclics Inc.

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Stephen Ansell, MD, PhD

Professor of Medicine
Department of Hematology
Mayo Clinical Cancer Center
Rochester, Minnesota

Stephen Ansell, MD, PhD, has disclosed that he has received funds for research support paid to his institution from Affimed, Bristol-Myers Squibb, Regeneron, Seattle Genetics, and Trillium.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no real or apparent conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no real or apparent conflicts of interest to report.
Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD, has no real or apparent conflicts of interest to report.

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower consults for Pfizer, Inc.; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist both from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with mantle cell lymphoma.

Goal

The goal of this activity is to improve participants’ competence and performance in treating patients with mantle cell lymphoma.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 13, 2018, through November 12, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Download this Clinical Care Options (CCO) PDF resource guide on optimal team management of patients with chronic myeloid leukemia (CML).

Jorge Cortes, MD Jenny Dahl, PA person default Caitlin R. Rausch, PharmD Released: September 16, 2019

Downloadable clinician resource on CLL including current treatment algorithm and select ongoing phase III clinical trials

Andrew D. Zelenetz, MD, PhD Released: September 10, 2019

Caron A. Jacobson, MD: Latest data and clinical potential for using CAR T-cells plus checkpoint inhibitors to overcome CAR T-cell–resistant DLBCL

person default Caron A. Jacobson, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 10, 2019 Expiration: September 9, 2020

Interactive online tool providing expert and guideline-based recommendations for assessing and managing adverse events associated with BTK inhibitors, from CCO

Jeremy S. Abramson, MD, MMSc Farrukh T. Awan, MD Christopher R. Flowers, MD, MS John P. Leonard, MD Julie M. Vose, MD, MBA Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: September 10, 2019 Expiration: September 9, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?